Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 1.00 |
| ▸ | FNTB | P49356 | 13/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7087230 | 0.92 | FNTA (1.00) | FNTAFNTBPGGT1BCYP3A4NR1H4 | |
| SCHEMBL6973193 | 0.87 | FNTA (0.77) | FNTAFNTBPGGT1BCYP3A4KDM4E | |
| SCHEMBL6971223 | 0.87 | FNTA (0.77) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL6972844 | 0.87 | FNTA (0.77) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL6598192 | 0.87 | FNTA (0.77) | FNTAFNTBPGGT1BCYP3A4NR1H4 | |
| SCHEMBL6974912 | 0.86 | FNTA (0.76) | FNTAFNTBPGGT1BCYP3A4KDM4E | |
| SCHEMBL6928044 | 0.86 | FNTA (0.82) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL6978517 | 0.86 | FNTA (0.76) | FNTAFNTBPGGT1BCYP3A4 | |
| SCHEMBL6600323 | 0.86 | FNTA (0.76) | FNTAFNTBPGGT1BCYP3A4NR1H4 | |
| SCHEMBL6972967 | 0.86 | FNTA (0.75) | FNTAFNTBPGGT1BCYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | claimed |
| EP-1656931-A1 | Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease | Exonhit Therapeutics SA (FR) | 2006-05-17 | — | — | EP | claimed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | claimed |
| EP-4659812-A1 | DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION | Bumm, Thomas (DE) | 2025-12-10 | — | — | EP | disclosed |
| WO-2011088126-A2 | TREATMENT OF VIRAL INFECTION WITH PRENYLTRANSFERASE INHIBITORS | EIGER BIOPHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | disclosed |
| US-20080090242-A1 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090242-A1 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| EP-1811984-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Exonhit Therapeutics SA (FR) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051423-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON’S DISEASE | EXONHIT THERAPEUTICS SA (FR) | 2006-05-18 | — | — | WO | disclosed |
| EP-1656931-A1 | Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease | Exonhit Therapeutics SA (FR) | 2006-05-17 | — | — | EP | disclosed |
| EP-1169320-B1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD (KR) | 2004-09-22 | — | — | EP | disclosed |
| US-6511978-B1 | For treating cancer, restenosis, atherosclerosis or viral infections | LG LIFE SCIENCES, LTD. (KR) | 2003-01-28 | — | — | US | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| WO-2001045710-A1 | PHARMACEUTICAL COMPOSITION CONTAINING [1-{[1-(1,3-BENZODIOXOL-5-YLMETHYL)-1H-IMIDAZOL-5-YL]METHYL}-4-(1-NAPHTHYL)-1H-PYRROL-3-YL](4-METHYL-1-PIPERAZINYL)METHANONE | LG CHEMICAL LTD. (KR) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045710-A1 | PHARMACEUTICAL COMPOSITION CONTAINING [1-{[1-(1,3-BENZODIOXOL-5-YLMETHYL)-1H-IMIDAZOL-5-YL]METHYL}-4-(1-NAPHTHYL)-1H-PYRROL-3-YL](4-METHYL-1-PIPERAZINYL)METHANONE | LG CHEMICAL LTD. (KR) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045710-A1 | PHARMACEUTICAL COMPOSITION CONTAINING [1-{[1-(1,3-BENZODIOXOL-5-YLMETHYL)-1H-IMIDAZOL-5-YL]METHYL}-4-(1-NAPHTHYL)-1H-PYRROL-3-YL](4-METHYL-1-PIPERAZINYL)METHANONE | LG CHEMICAL LTD. (KR) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | FNTA, GGPS1, FNTB | FNTA 1/4885FNTB 3/4885PGGT1B 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.